Here's My Pick for the Smartest High-Yield Dividend Stock to Buy Right Now

Kenvue reported second-quarter revenue of $3.95 billion, up 3% year over year, while EPS rose 9% to $0.24, supported by resilient demand for consumer-health brands including Tylenol and Listerine. The stock offers a 4.68% dividend yield and has a 64-year record of annual dividend increases. Its pending acquisition by Kimberly-Clark introduces dividend uncertainty, although the buyer is also a Dividend King with a roughly 5.23% yield and expects scale and cost-saving benefits from the combination.

Analysis

The relevant question is not dividend continuity but transaction credibility and capital-structure capacity. A KMB acquisition of KVUE would likely require substantial debt and/or equity financing; absent disclosed consideration, financing commitments, and a definitive agreement, KVUE's yield is not a reliable merger-arbitrage signal. For KMB, incremental leverage could constrain buybacks, slow dividend-growth cadence, and pressure its valuation multiple if promised cost synergies are back-end loaded.

Operationally, the combination has limited category overlap, so outright antitrust risk should be lower than execution risk. The value case depends on procurement, shared services, international distribution, and advertising efficiencies; these are harder to realize without disrupting brand investment, particularly in health-and-beauty categories where shelf velocity and promotional support determine share. JNJ is a modest second-order beneficiary only if a transaction validates the strategic value of separated consumer-health assets, but it has no material direct earnings exposure.

Over days, treat any KVUE strength without formal transaction documents as event-driven and potentially reversible. Over the next 1-3 months, the catalysts are a definitive price, financing structure, projected synergies, and regulatory filings; the critical 6-18 month issue is whether KMB can delever while preserving organic growth. Consensus may be over-crediting a high yield as downside protection: if a transaction fails or KMB signals debt-funded terms, KVUE can re-rate back toward standalone consumer-health multiples while KMB faces a leverage discount.

Key Decisions for Investors

• Do not initiate standalone KVUE merger-arbitrage exposure until a definitive agreement and cash/stock consideration are independently verified. Once announced, buy KVUE only if the annualized gross spread exceeds 10% after assigning a conservative close probability; otherwise the yield does not compensate for break risk.
• Set an alert for KMB financing disclosure: if pro forma net debt/EBITDA is projected above roughly 3.5x or management weakens its capital-return framework, consider a 3-6 month short KMB position versus long XLP as a leverage/multiple-compression hedge. Cover on credible asset-sale proceeds or synergy guidance sufficient to restore sub-3.0x leverage.
• If a cash-heavy deal is confirmed and KVUE trades at a meaningful discount to consideration, express the event through long KVUE / short KMB only after calculating the stock consideration beta and borrow cost. Falsify the trade on an FTC second-request signal, financing-market deterioration, or a spread narrowing below 5% annualized.
• For existing income exposure, prefer waiting for post-announcement KMB guidance rather than assuming the combined dividend is protected. A dividend-growth pause, credit-rating outlook revision, or weaker-than-expected organic sales would be a signal to reduce KMB even if the transaction closes.